Login to Your Account



Clinic Roundup


Thursday, March 15, 2012
• Oncothyreon Inc., of Seattle, said it enrolled the first patient in a Phase I trial of ONT-10, a therapeutic vaccine directed at MUC1. The study is designed to evaluate the safety and immunogenicity of the vaccine in patients with cancers that commonly express MUC1, including breast, non-small-cell lung, ovarian, colorectal, prostate, pancreatic and gastric cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription